Sensorion

132 articles with Sensorion

• Sensorion Reports Full-Year 2022 Financial Results and Business Update

  3/16/2023

  Sensorion a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces its full-year 2022 financial results and provides a business update.

• Sensorion Announces Agenda For R&D Day Showcasing Gene Therapy For Inner Ear Disease

  3/14/2023

  Sensorion, a pioneering clinical-stage biotechnology company, specialising in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the agenda for its R&D Day on Thursday 6 April 2023, at 8am EDT.

• Sensorion Discloses No Exposure To Silicon Valley Bank Closure

  3/13/2023

  Sensorion a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, has learned that Silicon Valley Bank has been closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation as receiver.

• Sensorion to Participate in the 6th Annual Bioprocessing Summit Europe

  3/7/2023

  Sensorion a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, is pleased to announce its participation in the 6th Annual Bioprocessing Summit Europe, held on 14-16 March, 2023, in Barcelona, Spain.

• Sensorion Further Strengthens Leadership, Appoints David Lawrence as Chief Financial Officer

  2/27/2023

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the appointment of David Lawrence as Chief Financial Officer, effective as of March 1st, 2023.

• Sensorion announces R&D Day focusing on its Gene Therapy programs

  2/21/2023

  Sensorion, a pioneering clinical-stage biotechnology company, specialising in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, invites you to attend its R&D Day on Thursday 6 April 2023, at 8 am EDT.

• Sensorion Will Present Two Posters at the Association for Research in Otolaryngology ARO 46th Annual MidWinter Meeting

  2/2/2023

  Sensorion is pleased to announce its participation, in-person, in the Association for Research in Otolaryngology 46th Annual MidWinter Meeting, taking place on February 11-15, 2023, in Orlando, Florida, United States.

• Sensorion and EVEON Collaborating to Develop an Injection System for the Delivery of Gene Therapy Treatments Into the Inner Ear

  1/31/2023

  Sensorion and EVEON announce they have been collaborating to design and develop an injection system for the delivery of Sensorion’s gene therapy products to the inner ear, including OTOF-GT product candidate.

• Sensorion Will Take Part in a Press Conference Launching the Annual UNESCO Week of Sound

  1/5/2023

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce the participation of its management team in a virtual press conference launching the annual UNESCO Week of Sound, an event sponsored by Sensorion, on January 10, 2023.

• Sensorion Announces First Patient Enrolled in Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity

  1/3/2023

  Sensorion announces that the first patient has been enrolled in its Phase 2a Proof of Concept clinical trial of SENS-401 in patients suffering from Cisplatin-Induced Ototoxicity.

• Sensorion Announces Its Attendance at the 41st Annual J.P. Morgan Healthcare Meeting in San Francisco

  12/5/2022

  Sensorion a pioneering clinical-stage biotechnology company, specialising in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce that its management team, including Chief Executive Officer Nawal Ouzren, will be attending the 41st Annual J.P. Morgan Healthcare Meeting, between 09-12 January 2023, in San Francisco, USA.

• Sensorion receives Orphan Drug Designation for OTOF-GT for the treatment of otoferlin gene-mediated hearing loss from the US Food and Drug Administration

  11/30/2022

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that the US Food and Drug Administration has granted Orphan Drug Designation to OTOF-GT, Sensorion’s lead gene therapy program, intended for the treatment of otoferlin gene mediated hearing loss.

• Sensorion Announces US FDA Grants Rare Pediatric Disease Designation to OTOF-GT for the Treatment of Otoferlin Gene-Mediated Hearing Loss

  11/7/2022

  Sensorion announces that the US Food and Drug Administration has granted Rare Pediatric Disease Designation to the Company’s lead therapy gene candidate, OTOF-GT, a gene therapy intended for the treatment of otoferlin gene mediated hearing loss.

• Sensorion Announces Approval to Initiate amended Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity in France

  10/24/2022

  Sensorion announces that the initiation of a Proof of Concept clinical trial of SENS-401 in patients with Cisplatin-Induced Ototoxicity has been approved by regulatory authorities in France.

• Sensorion to Present at the European Society of Gene & Cell Therapy (ESGCT) and the Gene Therapy for Rare Disorders Europe conferences in October 2022

  10/6/2022

  Sensorion is pleased to announce Sensorion's participation in two scientific conferences in October 2022.

• Sensorion to Participate in Various Upcoming September 2022 Investor Conferences

  9/26/2022

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the participation of Sensorion’s management in various upcoming investor conferences.

• Sensorion Reports 2022 First Half Results

  9/22/2022

  Sensorion announces its half-year results as of June 30, 2022, alongside its outlook for the remainder of 2022.

• Sensorion Announces First Patient Enrolled in Proof-of-Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

  9/14/2022

  Sensorion announces that the first patient has been enrolled in its proof-of-concept clinical trial of SENS-401 in patients scheduled for cochlear implantation.

• Sensorion Receives Positive Opinion for Orphan Drug Designation for OTOF-GT for the Treatment of Otoferlin Gene-Mediated Hearing Loss From the European Medicine Agency

  9/12/2022

  Sensorion announces that the European Medicines Agency Committee for Orphan Medicinal Products has adopted a positive opinion on Sensorion’s application for Orphan Drug Designation for its lead therapy gene candidate, OTOF-GT, a gene therapy intended for the treatment of otoferlin gene mediated hearing loss.

• Sensorion to participate in the Inner Ear Biology Workshop in September 2022

  9/8/2022

  Sensorion is pleased to announce Sensorion’s participation, in-person, in the Inner Ear Biology Workshop, taking place on September 10-13, 2022, in Trieste, Italy.